

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 November 2005 (17.11.2005)

PCT

(10) International Publication Number
WO 2005/107806 A1

(51) International Patent Classification⁷: **A61K 45/00**,
A61P 3/04

(21) International Application Number:
PCT/US2005/013193

(22) International Filing Date: 19 April 2005 (19.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/564,001 21 April 2004 (21.04.2004) US

(71) Applicant (for all designated States except US): **OREX-
IGEN THERAPEUTICS, INC.** [CA/US]; 28202 Cabot
Road, Suite 200, Laguna Niguel, CA 92677 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WEBER, Eckard**
[US/US]; 4040 Miller Street, San Diego, CA 92103 (US).
COWLEY, Michael Alexander [AU/US]; 6724 SE 19th
Avenue, Portland, OR 97202 (US).

(74) Agent: **MALLON, Joseph, J.**; 2040 Main Street, 14th
Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS FOR AFFECTING WEIGHT LOSS

(57) Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is a cannabinoid receptor antagonist. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

WO 2005/107806 A1

COMPOSITIONS FOR AFFECTING WEIGHT LOSS

Related Applications

[0001] This application claims priority to U.S. provisional Patent Application No. 60/564,001, entitled "COMPOSITIONS FOR AFFECTING WEIGHT LOSS," filed on April 21, 2004, and hereby incorporated by reference in its entirety.

Background of the Invention

Field of the Invention

[0002] The present invention is in the field of pharmaceutical compositions and methods for the treatment of obesity and for affecting weight loss in individuals.

Description of the Related Art

[0003] Obesity is a disorder characterized by the accumulation of excess fat in the body. Obesity has been recognized as one of the leading causes of disease and is emerging as a global problem. Increased instances of complications such as hypertension, non-insulin dependent diabetes mellitus, arteriosclerosis, dyslipidemia, certain forms of cancer, sleep apnea, and osteoarthritis have been related to increased instances of obesity in the general population.

[0004] Obesity has been defined in terms of body mass index (BMI). BMI is calculated as $\text{weight (kg)}/[\text{height (m)}]^2$. According to the guidelines of the U.S. Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) (World Health Organization. Physical status: The use and interpretation of anthropometry. Geneva, Switzerland: World Health Organization 1995. *WHO Technical Report Series*), for adults over 20 years old, BMI falls into one of these categories: below 18.5 is considered underweight, 18.5 – 24.9 is considered normal, 25.0 – 29.9 is considered overweight, and 30.0 and above is considered obese.

[0005] Prior to 1994, obesity was generally considered a psychological problem. The discovery of the adipostatic hormone leptin in 1994 (Zhang et al., "Positional cloning of the mouse obese gene and its human homologue," *Nature* 1994; 372:425-432) brought forth the realization that, in certain cases, obesity may have a biochemical basis. A corollary to this realization was the idea that the treatment of obesity may be achieved by chemical approaches. Since then, a number of such chemical treatments have entered the market. The most famous of these attempts was the

introduction of Fen-Phen, a combination of fenfluramine and phentermine. Unfortunately, it was discovered that fenfluramine caused heart-valve complications, which in some cases resulted in the death of the user. Fenfluramine has since been withdrawn from the market. There has been some limited success with other combination therapy approaches, particularly in the field of psychological eating disorders. One such example is Devlin, et al., Int. J. Eating Disord. 28:325-332, 2000, in which a combination of phentermine and fluoxetine showed some efficacy in the treatment of binge eating disorders. Of course, this disorder is an issue for only a small portion of the population.

[0006] In addition to those individuals who satisfy a strict definition of medical obesity, a significant portion of the adult population is overweight. These overweight individuals would also benefit from the availability of an effective weight-loss composition. Therefore, there is an unmet need in the art to provide pharmaceutical compositions that can affect weight loss without having other adverse side effects.

Summary of the Invention

[0007] Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is a cannabinoid receptor antagonist.

Detailed Description of the Preferred Embodiment

[0008] In a first aspect, the present invention is directed to a composition for the treatment of obesity or for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is a cannabinoid receptor antagonist.

[0009] In certain embodiments the opioid antagonist antagonizes a μ -opioid receptor (MOP-R) in a mammal. The mammal may be selected from the group consisting of mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, primates, such as monkeys, chimpanzees, and apes, and humans.

[0010] In some embodiments the opioid antagonist is selected from the group consisting of alvimopan, norbinaltorphimine, nalmeferine, naloxone, naltrexone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts or prodrugs thereof.


[0011] In other embodiments, the opioid antagonist is a partial opioid agonist. Compounds of this class have some agonist activity at opioid receptors. However, because they are weak agonists, they function as de-facto antagonists. Examples of partial opioid agonists include pentacozine, buprenorphine, nalorphine, propiram, and lofexidine.

[0012] The term “pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. Pharmaceutical salts can be obtained by reacting a compound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl) methylamine, and salts thereof with amino acids such as arginine, lysine, and the like.


[0013] A “prodrug” refers to an agent that is converted into the parent drug *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug, or may demonstrate increased palatability or be easier to formulate. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the “prodrug”) to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to provide the active moiety.

[0014] In some embodiments, the second compound is a cannabinoid receptor antagonist. Examples of this group of compounds include AM251 [*N*-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM281 [*N*-(morpholin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1*H*-indol-3-yl](4-methoxyphenyl)methanone), LY320135, and SR141716A (rimonabant), and

pharmaceutically acceptable salts or prodrugs thereof.. LY320135 and SR141716A have the following structures.



SR141716A



LY320135

[0015] In another aspect, the present invention relates to a method of affecting weight loss, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and antagonize cannabinoid receptor activity.

[0016] In certain embodiments, the individual has a body mass index (BMI) greater than 25. In other embodiments, the individual has a BMI greater than 30. In still other embodiments, the individual has a BMI greater than 40. However, in some embodiments, the individual may have a BMI less than 25. In these embodiments, it may be beneficial for health or cosmetic purposes to affect weight loss, thereby reducing the BMI even further.

[0017] In some embodiments, opioid receptor activity is antagonized by administering an opioid receptor antagonist. The opioid receptor antagonist may be a MOP receptor antagonist. In some embodiments, the opioid receptor antagonist is selected from alvimopan, norbinaltorphimine, nalmeferene, naloxone, naltrexone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts or prodrugs thereof.

[0018] In other embodiments, the cannabinoid receptor activity is antagonized by administering a cannabinoid receptor antagonist, as described herein.

[0019] In some embodiments, the treating step of the above method comprises administering to the individual a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is a cannabinoid receptor antagonist.

[0020] In some embodiments the first compound and the second compound are administered more or less simultaneously. In other embodiments the first compound is administered prior to the second compound. In yet other embodiments, the first compound is administered subsequent to the second compound.

[0021] In certain embodiments, the first compound and the second compound are administered individually. In other embodiments, the first compound and the second compound are covalently linked to each other such that they form a single chemical entity. The single chemical entity is then digested and is metabolized into two separate physiologically active chemical entities, one of which is the first compound and the other one is the second compound.

[0022] In another aspect, the present invention relates to a method of increasing satiety in an individual comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

[0023] In some embodiments, the treating step of the above method comprises administering to the individual a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is a cannabinoid receptor antagonist.

[0024] In some embodiments the first compound and the second compound are administered nearly simultaneously. In other embodiments the first compound is administered prior to the second compound. In yet other embodiments, the first compound is administered subsequent to the second compound.

[0025] In yet another aspect, the present invention relates to a method of suppressing the appetite of an individual comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

[0026] In some embodiments, the treating step of the above method comprises administering to the individual a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is a cannabinoid receptor antagonist.

[0027] In some embodiments the first compound and the second compound are administered nearly simultaneously. In other embodiments the first compound is administered prior to the second compound. In yet other embodiments, the first compound is administered subsequent to the second compound.

[0028] In another aspect, the present invention relates to a method of increasing energy expenditure in an individual comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

[0029] In some embodiments, the treating step of the above method comprises administering to the individual a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is a cannabinoid receptor antagonist.

[0030] In some embodiments the first compound and the second compound are administered nearly simultaneously. In other embodiments the first compound is administered prior to the second compound. In yet other embodiments, the first compound is administered subsequent to the second compound.

[0031] In certain embodiments disclosed herein, an individual is given a pharmaceutical composition comprising a combination of two or more compounds to affect weight loss. In some of these embodiments, each compound is a separate chemical entity. However, in other embodiments, the two compounds are joined together by a chemical linkage, such as a covalent bond, so that the two different compounds form separate parts of the same molecule. The chemical linkage is selected such that after entry into the body, the linkage is broken, such as by enzymatic action, acid hydrolysis, base hydrolysis, or the like, and the two separate compounds are then formed.

[0032] In another aspect, the invention relates to a pharmaceutical composition comprising a combination of an opioid antagonist and a cannabinoid receptor antagonist, as described above, or comprising a linked molecule, as described herein, and a physiologically acceptable carrier, diluent, or excipient, or a combination thereof.

[0033] The term "pharmaceutical composition" refers to a mixture of a compound of the invention with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, oral, injection, aerosol, parenteral, and topical administration. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

[0034] The term "carrier" defines a chemical compound that facilitates the incorporation of a compound into cells or tissues. For example dimethyl sulfoxide (DMSO) is a commonly utilized carrier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism.

[0035] The term "diluent" defines chemical compounds diluted in water that will dissolve the compound of interest as well as stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.

[0036] The term "physiologically acceptable" defines a carrier or diluent that does not abrogate the biological activity and properties of the compound.

[0037] The pharmaceutical compositions described herein can be administered to a human patient *per se*, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, 18th edition, 1990.

[0038] Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.

[0039] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly in the renal or cardiac area, often in a depot or sustained release formulation. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the organ.

[0040] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes.

[0041] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more

physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; *e.g.*, in Remington's Pharmaceutical Sciences, above.

[0042] For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0043] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipient with pharmaceutical combination of the invention, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0044] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0045] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in

admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

[0046] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0047] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0048] The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[0049] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0050] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

[0051] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

[0052] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0053] A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. A common cosolvent system used is the VPD co-solvent system, which is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of POLYSORBATE 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, *e.g.*, polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

[0054] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

[0055] Many of the compounds used in the pharmaceutical combinations of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, *etc.* Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free acid or base forms.

[0056] Pharmaceutical compositions suitable for use in the present invention include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0057] The exact formulation, route of administration and dosage for the pharmaceutical compositions of the present invention can be chosen by the individual physician in view of the patient's condition. (See *e.g.*, Fingl *et al.* 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p. 1). Typically, the dose range of the composition administered to the patient can be from about 0.5 to 1000 mg/kg of the patient's body weight. The dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient. Note that for almost all of the specific compounds mentioned in the present disclosure, human dosages for treatment of at least some condition have been established. Thus, in most instances, the present invention will use those same dosages, or dosages that are between about 0.1% and 500%, more preferably between about 25% and 250% of the established human dosage. Where no human dosage is established, as will be the case for newly-discovered pharmaceutical compounds, a suitable human dosage can be inferred from ED₅₀ or ID₅₀ values, or other appropriate values derived from *in vitro* or *in vivo* studies, as qualified by toxicity studies and efficacy studies in animals.

[0058] Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations regarding the dosage can be made. The daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.1 mg and 500 mg of each ingredient, preferably between 1 mg and 250 mg, *e.g.* 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of each ingredient between 0.01 mg and 100 mg, preferably between 0.1 mg and 60 mg, *e.g.* 1 to 40 mg of each ingredient of

the pharmaceutical compositions of the present invention or a pharmaceutically acceptable salt thereof calculated as the free base, the composition being administered 1 to 4 times per day. Alternatively the compositions of the invention may be administered by continuous intravenous infusion, preferably at a dose of each ingredient up to 400 mg per day. Thus, the total daily dosage by oral administration of each ingredient will typically be in the range 1 to 2000 mg and the total daily dosage by parenteral administration will typically be in the range 0.1 to 400 mg. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.

[0059] Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

[0060] Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.

[0061] In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

[0062] The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

[0063] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound of the invention formulated in a

compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

[0064] It will be understood by those of skill in the art that numerous and various modifications can be made without departing from the spirit of the present invention. Therefore, it should be clearly understood that the forms of the present invention are illustrative only and are not intended to limit the scope of the present invention.

Some Embodiments of the Invention

[0065] Some of the embodiments of the present invention are as follows:

[0066] In the first embodiment, the invention relates to a composition for affecting weight loss comprising a first compound and a second compound, wherein said first compound is an opioid antagonist and said second compound is a cannabinoid receptor antagonist.

[0067] In the second embodiment, the invention relates to the composition of the first embodiment, wherein said opioid antagonist antagonizes an opioid receptor in a mammal.

[0068] In the third embodiment, the invention relates to the composition of the second embodiment, wherein said opioid receptor is selected from a μ -opioid receptor (MOP-R), a κ -opioid receptor, and a δ -opioid receptor.

[0069] In the fourth embodiment, the invention relates to the composition of the second embodiment, wherein said opioid antagonist antagonizes a μ -opioid receptor (MOP-R) in a mammal.

[0070] In the fifth embodiment, the invention relates to the composition of the first embodiment, wherein said opioid antagonist is selected from the group consisting of alvimopan, norbinaltorphimine, nalmefene, naloxone, naltrexone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts or prodrugs thereof.

[0071] In the sixth embodiment, the invention relates to the composition of the first embodiment, wherein said opioid antagonist is a partial opioid agonist.

[0072] In the seventh embodiment, the invention relates to the composition of the sixth embodiment, wherein said partial opioid agonist is selected from the group consisting of pentacozine, buprenorphine, nalorphine, propiram, and lofexidine.

[0073] In the eighth embodiment, the invention relates to the composition of the first embodiment, wherein said second compound is selected from the group consisting of AM251 [N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM281 [N-(morpholin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone), LY320135, and SR141716A (rimonabant), and pharmaceutically acceptable salts or prodrugs thereof..

[0074] In the ninth embodiment, the invention relates to the composition of the first embodiment, wherein said first compound is naltrexone and said second compound is AM251.

[0075] In the tenth embodiment, the invention relates to the composition of the first embodiment, wherein said first compound is naloxone and said second compound is AM251.

[0076] In the eleventh embodiment, the invention relates to the composition of the first embodiment, wherein said first compound is nalmefene and said second compound is AM251.

[0077] In the twelfth embodiment, the invention relates to the composition of the eleventh embodiment, wherein the naltrexone is in a time-release formulation.

[0078] In the thirteenth embodiment, the invention relates to a method of affecting weight loss, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

[0079] In the fourteenth embodiment, the invention relates to the method of the thirteenth embodiment, wherein said individual has a body mass index greater than 25.

[0080] In the fifteenth embodiment, the invention relates to the method of the thirteenth embodiment, wherein opioid receptor activity is antagonized by administering an opioid receptor antagonist.

[0081] In the sixteenth embodiment, the invention relates to the method of the fifteenth embodiment, wherein the opioid receptor antagonist is a MOP receptor antagonist.

[0082] In the seventeenth embodiment, the invention relates to the method of the thirteenth embodiment, wherein the opioid receptor antagonist is selected from alvimopan, norbinaltorphimine, nalmefene, naloxone, naltrexone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts or prodrugs thereof.

[0083] In the eighteenth embodiment, the invention relates to the method of the fifteenth embodiment, wherein said opioid receptor antagonist is a partial opioid agonist.

[0084] In the nineteenth embodiment, the invention relates to the method of the eighteenth embodiment, wherein said partial opioid agonist is selected from the group consisting of pentacozine, buprenorphine, nalorphine, propiram, and lofexidine.

[0085] In the twentieth embodiment, the invention relates to the method of the thirteenth embodiment through the forty fifth embodiment, wherein cannabinoid receptor activity is antagonized by administering a compound selected from the group consisting of AM251 [N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM281 [N-(morpholin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone), LY320135, and SR141716A (rimonabant), and pharmaceutically acceptable salts or prodrugs thereof.

[0086] In the twenty first embodiment, the invention relates to the method of the thirteenth embodiment, wherein said first compound and said second compound are administered nearly simultaneously.

[0087] In the twenty second embodiment, the invention relates to the method of the twenty first embodiment, wherein said first compound is administered prior to said second compound.

[0088] In the twenty third embodiment, the invention relates to the method of the twenty second embodiment, wherein said first compound is administered subsequent to said second compound.

[0089] In the twenty fourth embodiment, the invention relates to a method of increasing satiety in an individual comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

[0090] In the twenty fifth embodiment, the invention relates to the method of the twenty fourth embodiment, wherein said treating step comprises administering to said individual a first compound and a second compound, wherein said first compound is an opioid antagonist and said second compound is a cannabinoid receptor antagonist.

[0091] In the twenty sixth embodiment, the invention relates to the method of the twenty fifth embodiment, wherein said first compound and said second compound are administered nearly simultaneously.

[0092] In the twenty seventh embodiment, the invention relates to the method of the twenty fifth embodiment, wherein said first compound is administered prior to said second compound.

[0093] In the twenty eighth embodiment, the invention relates to the method of the twenty fifth embodiment, wherein said first compound is administered subsequent to said second compound.

[0094] In the twenty ninth embodiment, the invention relates to a method of increasing energy expenditure in an individual comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

[0095] In the thirtieth embodiment, the invention relates to the method of the twenty ninth embodiment, wherein said treating step comprises administering to said individual a first compound and a second compound, wherein said first compound is an opioid antagonist and said second compound is a cannabinoid receptor antagonist.

[0096] In the thirty first embodiment, the invention relates to the method of the thirtieth embodiment, wherein said first compound and said second compound are administered nearly simultaneously.

[0097] In the thirty second embodiment, the invention relates to the method of the thirtieth embodiment, wherein said first compound is administered prior to said second compound.

[0098] In the thirty fourth embodiment, the invention relates to the method of the thirtieth embodiment, wherein said first compound is administered subsequent to said second compound.

[0099] In the thirty fifth embodiment, the invention relates to a method of suppressing the appetite of an individual comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

[0100] In the thirty sixth embodiment, the invention relates to the method of the thirty fifth embodiment, wherein said treating step comprises administering to said individual a first compound and a second compound, wherein said first compound is an opioid antagonist and said second compound is a cannabinoid receptor antagonist.

[0101] In the thirty seventh embodiment, the invention relates to the method of the thirty sixth embodiment, wherein said first compound and said second compound are administered nearly simultaneously.

[0102] In the thirty eighth embodiment, the invention relates to the method of the thirty sixth embodiment, wherein said first compound is administered prior to said second compound.

[0103] In the thirty ninth embodiment, the invention relates to the method of the thirty sixth embodiment, wherein said first compound is administered subsequent to said second compound.

[0104] In the fortieth embodiment, the invention relates to a method of affecting weight loss in an individual comprising identifying an individual in need thereof and treating that individual with a combination of naltrexone and AM251.

[0105] In the forty first embodiment, the invention relates to the method of the fortieth embodiment, wherein the individual has a BMI greater than 30.

[0106] In the forty second embodiment, the invention relates to the method of the fortieth embodiment, wherein the individual has a BMI greater than 25.

[0107] In the forty third embodiment, the invention relates to the method of the fortieth embodiment, wherein the naltrexone is in a time-release formulation.

[0108] In the forty fourth embodiment, the invention relates to the method of the forty third embodiment, wherein the plasma concentration level of both naltrexone and AM251 follow a similar concentration profile.

[0109] In the forty fifth embodiment, the invention relates to the method of the forty third embodiment, wherein the naltrexone and the AM251 are administered substantially simultaneously.

[0110] In the forty sixth embodiment, the invention relates to the method of the forty third embodiment, wherein the naltrexone is administered prior to the AM251.

[0111] In the forty seventh embodiment, the invention relates to the method of the forty third embodiment, wherein the naltrexone is administered subsequent to the AM251.

Examples

[0112] The examples below are non-limiting and are merely representative of various aspects of the invention.

Example 1: Combination of AM251 and naltrexone:

[0113] Individuals having a BMI of greater than 25 are identified. Each individual is instructed to take one 20 mg tablet of AM251 on a daily basis, in addition to one 50 mg tablet of naltrexone on a daily basis.

[0114] The individuals are monitored for a period of months. It is recommended that the dosage be adjusted so that each individual loses weight at a rate of 10% of initial weight every 6 months. However, the rate of weight loss for each individual may be adjusted by the treating physician based on the individual's particular needs.

[0115] If the initial dosage is not effective, then the AM251 dosage can be increased by 20 mg per day, though never exceeding 80 mg total per day. If the initial dosage results in a more rapid weight loss than the above rate, the dosage of each of AM251 or naltrexone can be reduced.

[0116] In some cases, it is beneficial to administer one dose of AM251 per day in conjunction with two or three or more doses of naltrexone throughout the day. Naltrexone may also be in a time-release formulation where the dose is administered once a day, but naltrexone gradually enters the blood stream throughout the day, or in the course of a 12 hour period.

Example 2: Combination of AM251 and nalmefene:

[0117] Individuals having a BMI of greater than 25 are identified. Each individual is instructed to take one 20 mg tablet of AM251 on a daily basis. In addition, each individual is injected with 1 mL of a solution of 100 µg of nalmefene in 1 mL of saline, intravenously, intramuscularly, or subcutaneously.

[0118] The individuals are monitored for a period of months. It is recommended that the dosage be adjusted so that each individual loses weight at a rate of 10% of initial weight every 6 months. However, the rate of weight loss for each individual may be adjusted by the treating physician based on the individual's particular needs.

[0119] If the initial dosage is not effective, then the AM251 dosage can be increased by 20 mg per day, though never exceeding 80 mg total per day. In addition, the dosage of nalmefene may be increased up to 2 mL of a solution of 1 mg of nalmefene in 1 mL of saline. If the initial dosage results in a more rapid weight loss than the above rate, the dosage of each of AM251 or nalmefene can be reduced.

Example 3: Combination of AM251 and naloxone:

[0120] Individuals having a BMI of greater than 25 are identified. Each individual is instructed to take one 20 mg tablet of AM251 on a daily basis. In addition,

each individual is injected with 1 mL of a solution of 400 µg of naloxone in 1 mL of saline, intravenously, intramuscularly, or subcutaneously.

[0121] The individuals are monitored for a period of months. It is recommended that the dosage be adjusted so that each individual loses weight at a rate of 10% of initial weight every 6 months. However, the rate of weight loss for each individual may be adjusted by the treating physician based on the individual's particular needs.

[0122] If the initial dosage is not effective, then the AM251 dosage can be increased by 20 mg per day, though never exceeding 80 mg total per day. If the initial dosage results in a more rapid weight loss than the above rate, the dosage of each of AM251 or nalmefene can be reduced.

Example 4 Dose-response experiments:

[0123] Seventy, four week old, male C57/B16J mice (Jackson Laboratory), 22-30 g were sham injected daily with 0.1 mL 0.9% saline (pH 7.4) for 1 week prior to the experiments. Animals were weighed and randomized to 1 of 7 weight-matched dose groups (0, 1.5, 3, 5.5, 10, 18, and 30 mg/kg; n=10/group for AM251; 0, 1.5, 3, 5.5, 10, 18, and 30 mg/kg; n=3/group for naltrexone) the day before experiments began. Food was removed between 4:30-5:30 pm the day before the experiment. Animals received a 0.3 mL bolus (AM251) or 0.1 mL bolus (naltrexone) intraperitoneal injection between 9-10:30 am, and food was provided immediately following injection. 3 animals/group received injections on each testing day (i.e., 3 runs of 3/group; 1 run of 1/group). Food was weighed 1, 2, 4, 8, and 24 h post-injection. Cumulative food intake $\pm$ SEM was calculated and analyzed using Prism. The SEM for these numbers were calculated to be between 0.0062 and 0.11. Doses were log transformed and fit to a sigmoidal curve, food intake was expressed as a proportion of the food intake in saline treated animals. From the curve, the EC₅₀ at each time point for each drug was determined.

[0124] The results are set forth in the table below:

	Hour 1	Hour 2	Hour 4	Hour 8	Hour 24
	MEAN	MEAN	MEAN	MEAN	MEAN
Saline	1.00	1.00	1.00	1.00	1.00
AM 251	0.97	0.85	0.88	0.90	0.99
Nalmefene	0.0083	0.11	0.57	0.81	0.98
AM 251 + Nalmefene	0.010	0.075	0.30	0.62	0.90

WHAT IS CLAIMED IS:

1. A composition for affecting weight loss comprising a first compound and a second compound, wherein said first compound is an opioid antagonist and said second compound is a cannabinoid receptor antagonist.
2. The composition of claim 1, wherein the opioid antagonist antagonizes an opioid receptor in a mammal, said opioid receptor selected from a μ -opioid receptor (MOP-R), a κ -opioid receptor, and a δ -opioid receptor.
3. The composition of claim 1, wherein the opioid antagonist is selected from the group consisting of alvimopan, norbinaltorphimine, nalmeferene, naloxone, naltrexone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts or prodrugs thereof.
4. The composition of claim 1, wherein the opioid antagonist is a partial opioid agonist.
5. The composition of claim 4, wherein the partial opioid agonist is selected from the group consisting of pentacozine, buprenorphine, nalorphine, propiram, and lofexidine.
6. The composition of claim 1, wherein said second compound is selected from the group consisting of AM251 [*N*-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM281 [*N*-(morpholin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1*H*-indol-3-yl](4-methoxyphenyl)methanone), LY320135, and SR141716A (rimonabant), and pharmaceutically acceptable salts or prodrugs thereof.
7. The composition of claim 1, wherein said first compound is naltrexone and said second compound is AM251 [*N*-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide].

8. The composition of claim 1, wherein said first compound is naloxone and said second compound is AM251 [*N*-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide].

9. The composition of claim 1, wherein said first compound is namafene and said second compound is AM251 [*N*-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide].

10. A method of affecting weight loss, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to antagonize cannabinoid receptor activity.

11. The method of the claim 10, wherein said individual has a body mass index greater than 25.

12. The method of the claim 10, wherein opioid receptor activity is antagonized by administering an opioid receptor antagonist.

13. The method of the claim 12, wherein the opioid receptor antagonist is a μ -opioid receptor (MOP-R) antagonist.

14. The method of the claim 12, wherein the opioid receptor antagonist is selected from alvimopan, norbinaltorphimine, nalmefene, naloxone, naltrexone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts or prodrugs thereof.

15. The method of the claim 12, wherein said opioid receptor antagonist is a partial opioid agonist.

16. The method of the claim 15, wherein said partial opioid agonist is selected from the group consisting of pentacozine, buprenorphine, nalorphine, propiram, and lofexidine.

17. The method of the claim 10, wherein cannabinoid receptor activity is antagonized by administering a compound selected from the group consisting of AM251 [*N*-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM281 [*N*-(morpholin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide], AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1*H*-indol-3-yl](4-methoxyphenyl)methanone), LY320135, and SR141716A (rimonabant), and pharmaceutically acceptable salts or prodrugs thereof.

18. A method of affecting weight loss in an individual comprising identifying an individual in need thereof and treating that individual with a combination of naltrexone and AM251.

19. The method of claim 18, wherein the individual has a BMI greater than 25.

20. The method of claim 18, wherein the plasma concentration level of both naltrexone and AM251 follow a similar concentration profile.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/013193

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K45/00 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 2004/122033 A1 (NARGUND RAVI P ET AL) 24 June 2004 (2004-06-24) paragraph '0894!	1-20
X	WO 2004/009015 A (MERCK & CO., INC; BANYU PHARMACEUTICAL CO., LTD; MACNEIL, DOUGLAS, J;) 29 January 2004 (2004-01-29) claims 2,7	1-20
X	CHEN ET AL: "Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake" BRAIN RES, vol. 999, January 2004 (2004-01), - 2004 pages 22-230, XP002334087 abstract	1-20

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

30 June 2005

Date of mailing of the international search report

12/07/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cattell, James

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2005/013193

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2004122033	A1	24-06-2004	NONE	
WO 2004009015	A	29-01-2004	AU 2003253925 A1	09-02-2004
			CA 2492225 A1	29-01-2004
			EP 1534074 A2	01-06-2005
			WO 2004009015 A2	29-01-2004